Clover Corporation Limited (ASX:CLV): Microencapsulated DHA Technology and FY26 Revenue Growth

Aditi Sarkar

14 October 2026 08:15 PM AEDT

Clover Corporation Limited (ASX:CLV): Microencapsulated DHA Technology and FY26 Revenue Growth

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Clover supplies encapsulated nutritional oils for infant formula and other food applications.
Its Driphorm product range enables sensitive oils to be incorporated into dry formulations.
FY26 revenue reached $97.4 million, an increase of 13%.
The company reported FY26 net profit after tax of $10.5 million, compared with $7.0 million.
Newer products and ARA powder demand featured in the September 2026 results announcement.

Clover Corporation Limited (ASX:CLV) develops and manufactures nutritional ingredients, including refined omega-3 oils and microencapsulated powders for infant formula, medical nutrition and food products. Its business combines oil processing and formulation technology, with FY26 performance reflecting demand for newer nutritional ingredients and developments in encapsulated products.

How Microencapsulation Supports DHA Applications

Through its Nu-Mega ingredients business, Clover Corporation Limited (ASX:CLV) offers Driphorm microencapsulated powders containing nutritional lipids. DHA, or docosahexaenoic acid, is an omega-3 fatty acid used in nutrition products. The company explains that encapsulation protects sensitive oils from oxidation and degradation, allowing them to be supplied in a dry powder format for incorporation into formulated products.

This distinction matters because manufacturers must consider the stability, handling and incorporation of oils when developing nutritional products. Clover Corporation Limited (ASX:CLV) markets powder and oil ingredients for various applications, rather than manufacturing finished infant formula. Product suitability depends on each customer’s formulation requirements and applicable food standards.

FY26 Revenue and Earnings Developments

For the financial year ended 31 July 2026, Clover Corporation Limited (ASX:CLV) reported revenue of $97.4 million, an increase of 13%. Net profit after tax reached $10.5 million, compared with $7.0 million in the preceding financial year. The company’s September 2026 results announcement attributed developments in performance partly to newer products and demand for ARA powders.

Revenue for the second half was $53.3 million, compared with $44.1 million in the first half, according to the FY26 results announcement. The company described second-half revenue as 10% higher than the comparable period. These figures illustrate the relationship between commercial uptake of nutritional ingredients and reported sales across its operating periods.

Product Mix and Commercial Execution

DHA and ARA ingredients serve different nutritional formulation requirements. Clover Corporation Limited (ASX:CLV) supplies nutritional oils and encapsulated ingredients to commercial customers, where product innovation can influence the range of formulations manufacturers can produce. Its company materials describe microencapsulation as a way to maintain oil stability and expand the formats in which nutritional lipids are used.

The FY26 results identify newer products and ARA powder demand as contributors to the reported earnings movement. However, the available primary-source material does not establish a quantified revenue contribution for each individual product line. Consequently, the relationship between total growth and individual DHA formulations should not be presented as a separately measured result.

Factors Affecting Future Operations

Clover Corporation Limited (ASX:CLV) operates in a specialised ingredient market where sales depend on customer orders, manufacturing capability, input sourcing and technical requirements. Maintaining product consistency and meeting food-related specifications are relevant operating considerations. Changes in demand across infant formula and other nutrition applications may also affect orders for particular ingredient formats.

Product innovation does not independently establish future revenue or earnings outcomes. For Clover Corporation Limited (ASX:CLV), subsequent company disclosures will provide the basis for assessing product mix, manufacturing performance and financial results after FY26.

Key Insights

Clover’s microencapsulation platform is central to its business of supplying DHA and other nutritional oils in formats suitable for food manufacturing. The FY26 results establish a documented increase in group revenue and reported net profit, while the company’s commentary links part of that performance to new products and ARA powders. Individual product profitability and future adoption cannot be determined from these disclosures alone.

FAQs

Q: What is Clover Corporation’s ASX ticker?

A:Clover Corporation Limited trades under ASX:CLV.

Q: What does Clover produce?

A:It supplies nutritional oils and microencapsulated ingredients for commercial food and nutrition applications.

Q: What is Driphorm?

A:Driphorm is the company’s range of microencapsulated nutritional oil powders.

Q: What revenue did Clover report for FY26?

A:The company reported $97.4 million for the financial year ended 31 July 2026.

Q: What contributed to FY26 earnings?

A:The company cited demand for newer products and ARA powders among the contributing factors.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.